Takeda Pharmaceutical plans to seek regulatory ​approval in Japan next year for its gastric cancer drug, after it extended overall survival and delayed disease ‌progression in a late-stage study, a company executive told Reuters.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in